1. trans -Dichloro(triphenylarsino)( N , N -dialkylamino)platinum(II) Complexes: In Search of New Scaffolds to Circumvent Cisplatin Resistance.
- Author
-
Hyeraci M, Agnarelli L, Labella L, Marchetti F, Di Paolo ML, Samaritani S, and Dalla Via L
- Subjects
- Cisplatin pharmacology, Cisplatin therapeutic use, Humans, Organoplatinum Compounds pharmacology, Platinum pharmacology, Platinum therapeutic use, Antineoplastic Agents, Ovarian Neoplasms drug therapy, Ovarian Neoplasms genetics, Ovarian Neoplasms metabolism
- Abstract
The high incidence of the resistance phenomenon represents one of the most important limitations to the clinical usefulness of cisplatin as an anticancer drug. Notwithstanding the considerable efforts to solve this problem, the circumvention of cisplatin resistance remains a challenge in the treatment of cancer. In this work, the synthesis and characterization of two trans -dichloro(triphenylarsino)( N , N -dialkylamino)platinum(II) complexes ( 1 and 2 ) were described. The trypan blue exclusion assay demonstrated an interesting antiproliferative effect for complex 1 in ovarian carcinoma-resistant cells, A2780cis. Quantitative analysis performed by ICP-AES demonstrated a scarce ability to platinate DNA, and a significant intracellular accumulation. The investigation of the mechanism of action highlighted the ability of 1 to inhibit the relaxation of supercoiled plasmid DNA mediated by topoisomerase II and to stabilize the cleavable complex. Cytofluorimetric analyses indicated the activation of the apoptotic pathway and the mitochondrial membrane depolarization. Therefore, topoisomerase II and mitochondria could represent possible intracellular targets. The biological properties of 1 and 2 were compared to those of the related trans -dichloro(triphenylphosphino)( N , N -dialkylamino)platinum(II) complexes in order to draw structure-activity relationships useful to face the resistance phenotype.
- Published
- 2022
- Full Text
- View/download PDF